z-logo
Premium
Tissue characterization of myocardial infarction using T 1ρ : Influence of contrast dose and time of imaging after contrast administration
Author(s) -
Huber Steffen,
Muthupillai Raja,
Lambert Brenda,
Pereyra Mercedes,
Napoli Alicia,
Flamm Scott D.
Publication year - 2006
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/jmri.20720
Subject(s) - contrast (vision) , medicine , myocardial infarction , infarction , nuclear medicine , radiology , cardiology , computer science , artificial intelligence
Purpose To determine whether contrast between acutely infarcted and normal myocardia in T 1 ‐rho‐weighted cine TFE (T 1ρ ‐TFE) and delayed‐enhancement (DE) images (measured using a metric percent enhancement (PE)) varied with the dose or time of imaging after contrast administration. Materials and Methods Eighteen patients with acute myocardial infarction (AMI) were randomly divided into three groups according to the dose of gadoversetamide (0.1, 0.2, or 0.3 mmol/kg) administered. After contrast administration, T 1ρ ‐TFE images were acquired at five and 40 minutes, and DE images were acquired at 10 and 30 minutes. Results For T 1ρ ‐TFE imaging the PE values at 40 minutes were 70 ± 14, 98 ± 14, and 105 ± 41 at 0.1, 0.2, and 0.3 mmol/kg dose levels, which were significantly greater than the corresponding PEs at five minutes after contrast administration (44 ± 12, 71 ±14, and 36 ± 13). For DE and T 1ρ ‐TFE imaging the dose of contrast agent did not significantly affect the PE. However, with DE the PE tended to increase with the dose. At all dose levels, irreversible injury was more conspicuous in T 1ρ ‐TFE images acquired at 40 minutes than at five minutes after contrast. Conclusion In T 1ρ ‐TFE, acute infarction was more conspicuous in images acquired at a later time point, and the PE did not vary with the contrast dose. J. Magn. Reson. Imaging 2006. © 2006 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here